IL2 and diabetes mellitus: Acceleration of diabetes onset resonates with previous reports that IL-2 and untethered IL-2/antibody complexes can exacerbate disease pathogenesis (Dong et al., 2021; Tang et al., 2008; Wesley et al., 2010), highlighting the safety, selectivity, and efficacy advantages for our IC.